• Vaccine Name: A. pleuropneumoniae ApxIa and ApxIIa protein vaccine
• Target Pathogen: Actinobacillus pleuropneumoniae
• Target Disease: porcine pleuropneumonia
• Vaccine Ontology ID: VO_0011384
• Type: Subunit vaccine
• Status: Research
• Antigen: A. pleuropneumoniae ApxIa and ApxIIa
• apxIIA gene engineering:
  • Type: Recombinant protein preparation
  • Description: The apxIIA gene was cloned from A. pleuropneumoniae serotype 5 isolated from the lungs of Korean pigs with pleuropneumonia. For the oral vaccine, S. cerevisiae expressing ApxIA antigen as well as the ApxIIA antigen were prepared (Shin et al., 2007).
  • Detailed Gene Information: Click Here.
• apxIA gene engineering:
  • Type: Recombinant protein preparation
  • Description: The apxIA gene was cloned from A. pleuropneumoniae serotype 5 isolated from the lungs of Korean pigs with pleuropneumonia. For the oral vaccine, S. cerevisiae expressing ApxIA antigen as well as the ApxIIA antigen were prepared (Shin et al., 2007).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000133
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000139
• Immunization Route: Oral immunization

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Briefly, 15 mice per group were subcutaneously injected with 100 µg of protein extract after emulsifying with complete Freund's adjuvant (Sigma, USA). This was then followed by a boost immunization with the same amount of antigens after emulsifying with incomplete Freund's adjuvant (Sigma, USA) at 2 weeks after the initial immunization. The final immunization was performed in the same manner at 2 weeks after the boost immunization. All groups were immunized orally through an oral gavage with 4 doses of Saccharomyces cerevisiae expressing either ApxIA (group C) or ApxIIA (group D) alone or both (group E) at 10-day intervals (Shin et al., 2007).
• Challenge Protocol: Mice in each group were challenged by intraperitoneal injection of a field isolate of A. pleuropneumoniae serotype 5 at 1.45 × 10^6 CFU (minimal lethal dose, MLD) in 10 days after their final immunization, and were then monitored every 6 h for up to 72 h (Shin et al., 2007).
• Efficacy: After the challenge, the mice in group E had a significantly lower infectious burden and a higher level of protection than the mice in the other groups (p < 0.05) (Shin et al., 2007).